Ruan - Newzino

Stories

iRegene photoreceptor cell therapy for retinitis pigmentosa cleared for trials in US and China

As of September 2026: Chief Financial Officer of iRegene Therapeutics; company holds US and China trial clearances for NouvSight001

About 1.5 million people worldwide have retinitis pigmentosa, an inherited disease that destroys the retina's light-sensing cells and can end in blindness. The only approved treatment covers patients with a specific RPE65 gene mutation — a small fraction of the affected population.

Updated Sep 29

Notable Quotes

The same underlying technology platform allows us to advance our pipeline globally and more efficiently.

from iRegene photoreceptor cell therapy for retinitis pigmentosa cleared for trials in US and China · Updated Sep 29

Globalization has been embedded in our R&D system since the company was founded. NouvNeu001 has given us hands-on experience advancing an iPSC-derived cell therapy across both the NMPA and FDA regulatory frameworks. NouvSight001 allows us to apply that experience to ophthalmology, a very different disease and tissue setting.

from iRegene photoreceptor cell therapy for retinitis pigmentosa cleared for trials in US and China · Updated Sep 29